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Abstract
The aim of this clinical trial (ID Number NCT01803347) was to determine the safety
and efficacy of autologous adipose-derived stem cells (ASCs) for treatment of
cryptoglandular fistula. This research was conducted following an analysis of the mis-
takes of a same previous phase III clinical trial. We designed a multicenter, random-
ized, single-blind clinical trial, recruiting 57 patients. Forty-four patients were
categorized as belonging to the intent-to-treat group. Of these, 23 patients received
100 million ASCs plus intralesional fibrin glue (group A) and 21 received intralesional
fibrin glue (group B), both after a deeper curettage of tracks and closure of internal
openings. Fistula healing was defined as complete re-epithelialization of external
openings. Those patients in whom the fistula had not healed after 16 weeks were eli-
gible for retreatment. Patients were evaluated at 1, 4, 16, 36, and 52 weeks and
2 years after treatment. Results were assessed by an evaluator blinded to the type of
treatment. After 16 weeks, the healing rate was 30.4% in group A and 42.8% in
group B, rising to 55.0% and 63.1%, respectively, at 52 weeks. At the end of the
study (2 years after treatment), the healing rate remained at 50.0% in group A and
had reduced to 26.3% in group B. The safety of the cellular treatment was confirmed
and no impact on fecal continence was detected. The main conclusion was that autol-
ogous ASCs for the treatment of cryptoglandular perianal fistula is safe and can favor
long-term and sustained fistula healing.
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1 | INTRODUCTION
Perianal fistula has an incidence of 1.1 to 2.2 per 10 000 persons per
year. The vast majority of cases are due to cryptoglandular disease.1,2 In
most patients, this condition may be successfully cured by surgery, but
surgical treatment of complex fistulas remains a challenge, with a high
rate of recurrence and frequent side effects such as fecal incontinence.3-5
Seventeen years ago, our group began to explore the use of adipose-
derived mesenchymal stromal cells (ASCs) as a treatment option for
patients with complex perianal fistula,6 hypothesizing that the immuno-
modulatory and anti-inflammatory capabilities of ASCs could contribute
to the healing process, improving outcomes as defined by fistula closure;
healing was defined as the absence of drainage through the external
openings and complete re-epithelization of these openings.7-9 In phase I
and II studies, the use of autologous ASCs was proved to be safe for the
treatment of fistulas having both a cryptoglandular and Crohn origin.10-12
A phase III clinical trial conducted to study cryptoglandular fistula using
autologous ASCs failed to find an advantage of the intervention over the
control group, possibly owing to issues related to the use of the cell prod-
uct and trial design. In the previous clinical trial, cell manipulation by either
vigorous agitation of the cell vials or use of hydrogen peroxide prior to cell
injection was inadequate, as both effects trigger cell death due to friction
or toxicity. In addition, control of the cell implant was not exhaustive,
causing high injection speed and not always in the appropriate areas.13
Later, a phase III clinical trial in Crohn perianal fistula using allogeneic
ASCs showed a clear advantage when using these cells over the control
group,14 particularly in long-termevaluation.15
The aim of this randomized clinical trial (RCT) was to investigate the
efficacy of autologous ASCs for treatment of complex cryptoglandular
perianal fistula; taking into account previous mistakes and shortcomings,
especially as concerns cell manipulation, we should consider it a live
medicine. Four modifications were introduced with respect to the previ-
ous phase III RCT: exhaustive control of cell manipulation, clear definition
of complex fistula, larger number of cells implanted, and the use of cul-
turedmedia containing platelet lysate instead of serum.
2 | MATERIALS AND METHODS
This study (EudraCT number 2012-001178-28) was conducted in
accordance with the Note for Guidance on Good Clinical Practice
(CPMP/ICH/135/95 of 1 May 1996), Royal Decree 223/2004 of
February 2004, and the Declaration of Helsinki (version revised in
Seoul, 2008). The trial was approved by the Spanish Agency of Medi-
cines and Medical Devices (AEMPS number, MUH/AEC. 05/09/2012)
and by the local ethics committees (HULP3617.05/07/2012)
according to Spanish and European legislation and was registered in
the clinicaltrials.gov (NCT0180334757) database.
The sample size (population calculation) comprised 80 patients to
be randomized and treated, so five Spanish hospitals were included in
the trial; however, only 57 patients met the inclusion criteria and did
not present any of the exclusion criteria (Figure 1). Briefly, all included
patients presented complex perianal fistula of cryptoglandular origin
with no indications of inflammatory bowel disease. Forty-four com-
pleted the assigned treatment and were evaluable (intention-to-treat
[ITT] population). Diagnosis of complex fistula was performed by physi-
cal examination and magnetic resonance imaging (MRI) in all patients.
Treatment results were evaluated by an investigator blinded to the
treatment at 1, 4, 16, 36, and 52 weeks as well as 2 years after the last
treatment. Healing was defined as the absence of drainage through the
external openings and complete re-epithelization of these openings.
2.1 | Protocol design
A multicenter, single-blinded, randomized, add-on clinical trial was
performed using two parallel groups. Patients were enrolled from April
2013 through June 2016. During the screening visit, an independent
organization (Effice Research, Madrid, Spain) randomly assigned
patients in a 1:1 ratio to receive either of two treatments: surgery pro-
tocol plus 100 million ASCs plus fibrin glue (group A), or surgery pro-
tocol plus fibrin glue (group B). Patients were blinded to the therapy
administered; surgeons involved in treatment administration and
follow-up were not. An independent surgeon with no knowledge of
the treatment administered (blinded) evaluated fistula healing at
weeks 16 and 52 and 2 years after treatment.
If the fistula remained open at week 16 (primary endpoint), a sec-
ond dose of ASC plus fibrin glue (group A) or fibrin glue alone (group
B) was administered, and the patient was reassessed according to the
same protocol.
Incontinence was assessed by patients themselves using theWexner
score and quality of life using SF-12 questionnaire during follow-up.
At least 2 weeks prior to therapy administration, all patients
underwent liposuction for manufacturing of ASCs to be used during
the study (group A) or for cryopreservation (group B). Liposuction was
performed by plastic surgeons with patients under sedation and local
anesthesia, obtaining at least 100 mL of fat lipoaspirate. This material
was sent in a hermetic and sterile system at 2C-8C to clean room
laboratories production (“Clínica Universidad de Navarra” or “Hospital
Universitario de Salamanca”) according to the randomization protocol
established by Effice Research. Once in these laboratories, the sam-
ples were processed under Good Manufacturing Practices conditions
and cryopreserved. The final cell dose was 100 × 106 ASCs prepared
at a concentration of 10 million cells per milliliter in 2-mL vials.
Significance statement
Autologous mesenchymal stem cells treatment for complex
perianal fistula is safe, but according to the current results, it
seems to provide an advantage over a good surgical proto-
col at 2 years after treatment and then results are similar to
those shown with allogenic mesenchymal stem cells in pre-
vious clinical trials.
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Samples from each vial were tested before release as described
below. Fibrin glue (Baxter Inc, Spain) was used at a dose of 2-5 mL
according to recommendations (1 mL per 4 cm2 of surface area).
Treatments were administered in an operating room according to a
standard surgical protocol, as described in “A Step-By-Step Surgical
Protocol for the Treatment of Perianal Fistula with Adipose-Derived
Mesenchymal Stem Cells”,16 and with external control during the surgi-
cal procedure in all cases. In brief, before injection of cells (or saline
solution in group B), deep curettage of all tracts was performed and the
internal opening was closed with the use of stitches. Half of each dose
was injected around the internal opening, and the other half through
the external opening. Finally, the fistula tract was filled with fibrin glue.
2.2 | Follow-up and efficacy assessment
Clinical evaluation of fistula healing, SF-12 questionnaire, and Wexner
incontinence score were assessed at 1, 4, 16, 36, and 52 weeks after
treatment. The incidence of adverse events (AEs) and serious adverse
events (SAEs) was assessed at each study visit. An independent sur-
geon blinded to the treatment arm assessed healing at week 16, 36,
and 52. Healing was defined as the absence of drainage through an
external opening and complete re-epithelization of the external open-
ing. Considering the results of efficacy at 1 year, we requested ethics-
committee permission to perform a retrospective study to carry out
long-term follow-up (2 years) of the patients included in the study,
with particular emphasis on long-term safety and recurrence of healed
fistulas. A final follow-up was scheduled 2 years after the last treat-
ment to determine the final state of healing and perianal suppuration.
2.3 | Statistical analysis
All statistical analyses were performed by Effice Research. The demo-
graphic and clinical data of the study subjects were described using
means and SD of descriptive statistical indices. Quantitative variables
were analyzed by calculating the 95% confidence interval (CI) and rel-
ative and absolute frequencies. Closure of the fistula was described
by frequency, percentage, and 95% CI for the total sample and by
treatment group and compared with the chi-square test. To compare
fistula evolution over time, the Student t test of related samples
(or the test of signed ranges in the case of lack of normality) was used
for quantitative variables. All statistical analyses were performed using
SAS statistical package, version 9.4 (SAS Institute, Cary, North Caro-
lina). The reliability and accuracy of the analyses were guaranteed at
all times. In all statistical tests performed with the outcome variables,
a statistical significance level of .05 was used. To determine the nor-
mality of the distributions, the Shapiro-Wilk test was used.
3 | RESULTS
As shown in Figure 2, the ITT population comprised 56 patients out of
the 57 subjects enrolled. Forty-four were randomized (ITT population)
and 39 underwent follow-up (per protocol [PP] population). All
patients in both groups showed similar demographic and clinical char-
acteristics at baseline (Table 1).
The fistula healing rate 16 weeks after the first treatment was
36.4% (95% CI, 13.2-52.9; 7 patients out of 23) for group A and
42.8% (95% CI, 21.8-65.9; 9 patients out of 21) for group B. Of the
28 patients in whom the fistula was not closed, 23 were treated again,
which resulted in closure in an additional patient in group A and 3 in
group B. Therefore, at 52 weeks, 23 out of 44 patients showed com-
plete closure of the fistula (52.3% of the ITT population and 58.97 of
the PP population), that is, 11 (55% of the PP population) patients in
group A and 12 (63% of PP population) patients in group B; no statis-
tically significant differences were observed between groups
(P = .605). Recurrence of the fistula was observed at 2-year follow-up
in eight previously cured patients: one in group A (ASCs plus fibrin
glue) and seven in group B (fibrin glue alone). Hence, the final results
showed that in 15 of 39 patients who completed the trial
(PP population), the fistula remained closed 2 years later (38.46%);
10 out of these 20 patients (50.0% of the PP population) were treated
with cells (group A), and 5 out of 19 (26.3% of the PP population)
were treated with fibrin glue (group B; Figure 3; P = .129).
We found no other statistically significant differences in other
study endpoints, such as fecal incontinence grade (Wexner score) or
quality of life indexes (SF-12; data not shown).
F IGURE 1 Inclusion and exclusion criteria
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We did not observe other intergroup differences in the clinical
evolution of patients (data not shown). Twenty-seven AEs were
recorded in 16 patients (36.4%), that is, 11 AEs in 7 patients treated
with ASCs plus fibrin glue (30.4%) and 16 events affecting 9 patients
in the fibrin glue-only group (42.9%). None of the AEs were related to
the treatment; these included back pain, urticaria, renal colic, and eye
infection. There were five SAEs in five patients (11.4%), one in a
patient treated with ASCs plus fibrin glue (4.3%) and four in patients
treated with fibrin glue (19.0%). Of the five SAEs, three were perianal
abscesses, one prolapsed, and one schizophrenic episode (Table 2).
4 | DISCUSSION
This RCT was designed to determine the efficacy of autologous ASCs
for the treatment of cryptoglandular complex perianal fistula. Here,
we sought to correct the design errors observed during the previous
phase III trial (FATT-1)13 and taking into account the results of the
previous phase II clinical trials.11,12 During the phase II trial, which
was unblinded, a healing rate of 71% was observed, with a low recur-
rence rate and no risk of fecal incontinence. Unfortunately, the results
of the phase II trial could not be confirmed in FATT-1, a phase III
study (blinded), as the safety of ASC therapy was demonstrated but
the healing rate was 43.3% when using autologous ASCs plus fibrin
glue (after a second dose, where applicable), which was not signifi-
cantly different from the control group comprising patients treated
with fibrin glue alone (37.29%). A detailed analysis of the FATT-1 trial
revealed a number of flaws, most of which were related to the manip-
ulation of the cell product, which included vigorous agitation of the
vials to resuspend the cells, use of hydrogen peroxide to wash out the
fistulous tract, and poor selection of patients associated with a misin-
terpretation of the definition of complex fistula. In order to correct
these flaws, we decided to implement the following corrective mea-
sures: establish a clear definition of “complex fistula,” use a new stan-
dardized, monitored surgical procedure, institute exhaustive control
over manipulation and cell injection, and increase the cell dose to
100 million per injection (considering the excellent safety profile).
F IGURE 2 Flow-chart diagram. The reasons for exclusion of
patients were as follows: 20 for screening failure, 3 for HCV+, 1 for
HBV+, 8 for quantiferon+, 2 by patient decision, and 2 for no cell
growth. The reason for lost to follow-up was in all cases by patient
decision. ASCs, autologous adipose-derived stem cells; ITT, intent-to-
treat population (patients who had received at least 1 dose of
treatment); PP, per-protocol population (patients without major
protocol deviations)
F IGURE 3 Efficacy flow-chart. ASCs, autologous adipose-derived
stem cells
TABLE 1 Demographic and clinical characteristics at baseline (ITT
population)
A B
Group (n = 23) (n = 21)
Age (years), mean (SD) 50.10 (10.7) 50.86 (9.64)
Male, n (%) 16 (72.70) 14 (66.70)
Female, n (%) 7 (27.33) 7 (33.33)
Caucasian, n (%) 23 (100) 21 (100)
General physical condition
Height (cm), mean (SD) 172.25 (9.26) 172.11 (9.42)
Weight (kg), mean (SD) 82.83 (15.25) 86.00 (19.48)
Systolic blood pressure
(mm Hg), mean (SD)
12511 (168) 12344 (223)
Diastolic blood pressure
(mm Hg), mean (SD)
7394 (128) 7214 (164)
Heart rate (beats/min),
mean (SD)
7584 (937) 7425 (836)
Note: Group A was treated with ASCs plus fibrin glue; group B was treated
with fibrin glue.
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After 1 year of follow-up in the current RCT, no differences were
found between patients receiving cells and those of the control group,
this despite the aforementioned corrective measures. Nevertheless, at
2-year follow-up, a significant change was observed, as seven of the
cured patients from the control group (fibrin glue alone) showed
recurrence as compared with only one patient from the cell group.
Hence, the final results indicate that on long-term evaluation, twice as
many patients treated using autologous ASCs plus fibrin glue had a
fully cured fistula, in comparison with fibrin glue alone (50% ASC
group vs 26% control group). These improved results on the long-term
assessment reflect the long-term results of the previous phase II12
and phase III (FATT-1)13 RCTs and from other clinical trials in Crohn
disease using allogeneic ASCs and reporting on long-term assess-
ment.15 These long-term improvements can be explained by the bio-
logical action of these types of cells.17-19
The results obtained in the control group merit commentary.
Although we treated cases classified as “complex fistula,” more than
60% of the patients who received two doses of fibrin glue under our
minimally invasive surgical protocol had complete resolution of the
fistula 1 year later, and these results were better than those associ-
ated with a more aggressive surgical protocol.20 We consider that the
new surgical protocol based on a “cleaning surgery” (deep curettage)
played a major role in the high number of fistula closures observed in
both groups, particularly when considering that all patients had under-
gone more than two failed surgeries before being included in this trial.
However, we must consider that in this RCT we eliminated the “pla-
cebo effect,” as it has been shown to have a powerful influence in the
field of stem cell therapy, because we evaluated all results by a sur-
geon blinded to treatment group. As a result, we observed a high
number of long-term recurrences in the control group. According to
Figure 3, at 2 years, only 23% maintained cured status. Hence, we can
conclude that this “cleaning surgery” does not provide lasting resolu-
tion, possibly because the inflammatory focus remains. In this sce-
nario, stem cells (ASCs) and their anti-inflammatory effects can favor
long-term healing, improving the results up to 50%. It should be
emphasized that this is minimally invasive surgery and as such does
not produce SAEs such as fecal incontinence. We observed a clear
tendency toward better results in the long-term evaluation when stem
cells were used in cryptoglandular surgery, possibly related to the
notion that the cell works as a “living medicine” with long-term
effects.21,22
Another finding from our trial is related to the method used for
ASC expansion and culture. Unlike in other studies, here ASCs were
expanded using human platelet lysate in the culture media, which may
have the advantage of avoiding the use of animal-derived factors.
Human platelet lysate is widely used to grow MSCs,23-25 and many
studies have demonstrated that this confers a degree of safety that is
at least equivalent to that offered by fetal bovine serum.26,27 Indeed,
some studies have suggested that the use of platelet lysate may
increase cell yield and shorten the time for ex vivo expansion without
epigenetic alterations.25,27
One of the issues regarding the use of somatic cell medicinal
products has been the selection of the cell dose. In general, deci-
sions regarding dose levels were based on studies performed in
animals, the absence of AEs, and the number of cells that can be
generated in a particular period. Although some studies have
suggested a relation between cell dose—or even the number of
doses—and efficacy, there has been no evidence of a dose-response
relation.28-30 One of our goals was to gain insight as to whether a
larger cell dose would yield an increase in efficacy. Our results con-
firm the high safety profile but, unfortunately, no significant
increase in efficacy.
The main limitation in this RCT had been that the low number of
patients recruited or the high number of patients who did not com-
plete the study may have had an impact on the results. We believe
that the highly restrictive inclusion criteria used may have limited
patient participation, and the exhaustive control and follow-up is likely
to have caused many patients to drop out of the trial.
Other limitation in this RCT would be that because of the mecha-
nism of action of the ASCs, it may be advisable to use allogeneic ASCs
from selected healthy donors and avoid liposuction. Patients with
Crohn disease have an inflammatory process, and because of the anti-
inflammatory proprieties of ASCs, we expect better results in this con-
dition. This way, the use of allogeneic cells for the treatment of Crohn
fistulous pathology is, to date, the only one that has reported efficacy
results in a phase III clinical trial.14 It also has the added advantage of
select cells (the best donor) and faster treatment and avoids possible
setbacks (contamination, culture problems, etc.) from the removal of
adipose tissue to implant during production and/or transport. It
should be stressed, however, that ASCs from patients with inflamma-
tory diseases display functional abnormalities and lower inflammatory
capacities.31-33 Furthermore, it seems important to define the fistu-
lous disease to be treated.
In summary, we observed a clear trend toward better long-term
results when stem cells were used to treat complex cryptoglandular
fistula, and this method confers no risk of fecal incontinence.
TABLE 2 Related serious adverse
events (SAE)
Treatment group SAE Outcome Intensity Causality
A Perianal abscess Resolved Mild Related
B Perianal abscess Resolved Severe Related
B Prolapse Resolved Severe Not related
B Schizophrenic episode Resolved Severe Not related
B Perianal abscess Resolved Mild Related
Note: Treatment groups: A, was treated with ASCs plus fibrin glue; B, was treated with fibrin glue.
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5 | CONCLUSION
Although the findings of this study indicate that autologous ASC
treatment for complex perianal fistula is safe, it seems that this proce-
dure only provides an advantage over interventions based on a good
surgical protocol at 2 years after treatment and is similar to the use of
allogenic mesenchymal stem cells in previous clinical trials.
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